Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy

American Journal of Ophthalmology

Volumn 156, Issue 1, 2013, Pages

  Sato, Taku ^a   Kishi, Shoji ^a   Matsumoto, Hidetaka ^a   Mukai, Ryo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; ARTICLE; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA TEAR; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84879198220     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.02.006     Document Type: Article

References (43)

1. L.A. Yannuzzi, A. Ciardella, R.F. Spaide, M. Rabb, K.B. Freund, and D.A. Orlock The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy Arch Ophthalmol 115 4 1997 478 485
2. A.K. Kwok, T.Y. Lai, C.W. Chan, E.L. Neoh, and D.S. Lam Polypoidal choroidal vasculopathy in Chinese patients Br J Ophthalmol 86 8 2002 892 897
3. I. Maruko, T. Iida, M. Saito, D. Nagayama, and K. Saito Clinical characteristics of exudative age-related macular degeneration in Japanese patients Am J Ophthalmol 144 1 2007 15 22
4. R.F. Spaide, I. Donsoff, and D.L. Lam Treatment of polypoidal choroidal vasculopathy with photodynamic therapy Retina 22 5 2002 529 535
5. S.C. Lee, Y.S. Seong, S.S. Kim, H.J. Koh, and O.W. Kwon Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula Ophthalmologica 218 3 2004 193 201
6. W.M. Chan, D.S. Lam, and T.Y. Lai Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy Ophthalmology 111 8 2004 1576 1584
7. A. Otani, M. Sasahara, and Y. Yodoi Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 144 1 2007 7 14
8. E. Akaza, M. Yuzawa, Y. Matsumoto, S. Kashiwakura, K. Fujita, and R. Mori Role of photodynamic therapy in polypoidal choroidal vasculopathy Jpn J Ophthalmol 51 4 2007 270 277
9. Y. Tano Ophthalmic PDT Study Group: guidelines for PDT in Japan Ophthalmology 115 3 2008 585-585.e6
10. E. Akaza, R. Mori, and M. Yuzawa Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy Retina 28 5 2008 717 722
11. Y. Kurashige, A. Otani, and M. Sasahara Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 146 4 2008 513 519
12. D. Tsuchiya, T. Yamamoto, R. Kawasaki, and H. Yamashita Two-year outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions Retina 29 7 2009 960 965
13. S. Leal, R. Silva, and J. Figueira Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up Retina 30 8 2010 1197 1205
14. Y. Ojima, A. Tsujikawa, A. Otani, Y. Hirami, H. Aikawa, and N. Yoshimura Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy Am J Ophthalmol 141 5 2006 958 960
15. Y. Hirami, A. Tsujikawa, and A. Otani Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy Retina 27 3 2007 335 341
16. F. Gomi, M. Sawa, and H. Sakaguchi Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 92 1 2008 70 73
17. A. Tsujikawa, S. Ooto, K. Yamashiro, H. Tamura, A. Otani, and N. Yoshimura Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab Jpn J Ophthalmol 54 4 2010 310 319
18. G.T. Kokame, L. Yeung, and J.C. Lai Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results Br J Ophthalmol 94 3 2010 297 301
19. H. Koizumi, T. Yamagishi, T. Yamazaki, and S. Kinoshita Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 95 11 2011 1555 1559
20. T. Hikichi, M. Higuchi, and T. Matsushita One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients Am J Ophthalmol 154 1 2012 117 124
21. A. Koh, W.K. Lee, and L.J. Chen EVEREST Study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 8 2012 1453 1464
22. J.S. Heier, D.S. Boyer, and T.A. Ciulla Focus study group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study Arch Ophthalmol 124 11 2006 1532 1542
23. P.K. Kaiser Registry of Visudyne AMD Therapy writing committee Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Ophthalmology 116 4 2009 747 755
24. M. Larsen, U. Schmidt-Erfurth, and P. Lanzetta Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results Ophthalmology 119 5 2012 992 1000
25. P. Ruamviboonsuk, M. Tadarati, S. Vanichvaranont, P. Hanutsaha, and N. Pokawattana Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study Br J Ophthalmol 94 8 2010 1045 1051
26. A.A. Rouvas, T.D. Papakostas, A. Ntouraki, M. Douvali, I. Vergados, and I.D. Ladas Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy Retina 31 3 2011 464 474
27. F. Ricci, A. Calabrese, F. Regine, F. Missiroli, and A.P. Ciardella Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy Retina 32 7 2012 1280 1288
28. M. Saito, T. Iida, and M. Kano Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy Retina 32 7 2012 1272 1279
29. K. Tomita, A. Tsujikawa, and K. Yamashiro Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab Am J Ophthalmol 153 1 2012 68 80
30. T. Sato, S. Kishi, H. Matsumoto, and R. Mukai Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy Am J Ophthalmol 149 6 2010 947 954
31. F. Gomi, M. Sawa, T. Wakabayashi, Y. Sasamoto, M. Suzuki, and M. Tsujikawa Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 150 1 2010 48 54
32. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, M.K. Ezzat, and R.J. Singh Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 12 2007 2179 2182
33. T.U. Krohne, N. Eter, F.G. Holz, and C.H. Meyer Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 4 2008 508 512
34. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2 Arch Ophthalmol 119 2 2001 198 207
35. P. Heiduschka, H. Fietz, and S. Hofmeister Penetration of bevacizumab through the retina after intraretinal injection in the monkey Invest Ophthalmol Vis Sci 48 6 2007 2814 2823
36. J. Shahar, R.L. Avery, and G. Heilweil Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) Retina 26 3 2006 262 269
37. J.P. Tong, W.M. Chan, and D.T. Liu Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization Am J Ophthalmol 141 3 2006 456 462
38. H. Nakashizuka, M. Mitsumata, and S. Okisaka Clinicopathologic findings in polypoidal choroidal vasculopathy Invest Ophthalmol Vis Sci 49 11 2008 4729 4737
39. M. Matsuoka, N. Ogata, T. Otsuji, T. Nishimura, K. Takahashi, and M. Matsumura Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy Br J Ophthalmol 88 6 2004 809 815
40. A. Okubo, M. Sameshima, A. Uemura, S. Kanda, and N. Ohba Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study Br J Ophthalmol 86 10 2002 1093 1098
41. U. Schmidt-Erfurth, U. Schlötzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G.O. Naumann Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 10 2003 2147 2154
42. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, and G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
43. H.J. Cho, J.S. Baek, D.W. Lee, C.G. Kim, and J.W. Kim Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy Korean J Ophthalmol 26 3 2012 157 162